Solmi M, Radua J, Olivola M, Croce E, Soardo L, Salazar de Pablo G, et al. Age at onset of mental disorders worldwide: large-scale meta-analysis of 192 epidemiological studies. Mol Psychiatry. 2021;27:281–95.

Essau CA, Lewinsohn PM, Olaya B, Seeley JR. Anxiety disorders in adolescents and psychosocial outcomes at age 30. J Affect Disord. 2014;163:125–32.

Article  PubMed  PubMed Central  Google Scholar 

Ginsburg GS, Becker-Haimes EM, Keeton C, Kendall PC, Iyengar S, Sakolsky D, et al. Results from the child/adolescent anxiety multimodal extended long-term study (CAMELS): primary anxiety outcomes. J Am Acad Child Adolesc Psychiatry. 2018. https://doi.org/10.1016/j.jaac.2018.03.017.

Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the national comorbidity survey replication. Arch Gen Psychiatry. 2005;62:593.

Article  PubMed  Google Scholar 

Warner EN, Ammerman RT, Glauser TA, Pestian JP, Agasthya G, Strawn JR. Developmental epidemiology of pediatric anxiety disorders. Child Adolesc Psychiatr Clin N Am. 2023;32:511–30.

Article  PubMed  Google Scholar 

Beesdo K, Pine DS, Lieb R, Wittchen H-U. Incidence and risk patterns of anxiety and depressive disorders and categorization of generalized anxiety disorder. Arch Gen Psychiatry. 2010;67:47–57.

Article  PubMed  Google Scholar 

Lutz B, Marsicano G, Maldonado R, Hillard CJ. The endocannabinoid system in guarding against fear, anxiety and stress. Nat Rev Neurosci. 2015;16:705–18.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gunduz-Cinar O, Hill MN, McEwen BS, Holmes A. Amygdala FAAH and anandamide: Mediating protection and recovery from stress. Trends Pharm Sci. 2013;34:637–44.

Article  CAS  PubMed  Google Scholar 

Baumel WT, Strawn JR. Neurobiology of treatment in pediatric anxiety disorders. Child Adolesc Psychiatr Clin N Am. 2023;32:589–600.

Article  PubMed  Google Scholar 

Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio MG, et al. The endogenous cannabinoid system controls extinction of aversive memories. Nature. 2002;418:530–4.

Article  CAS  PubMed  Google Scholar 

Hillard CJ. The endocannabinoid signaling system in the CNS: a primer. Int Rev Neurobiol. 2015;125:1–47.

Article  CAS  PubMed  PubMed Central  Google Scholar 

deRoon-Cassini TA, Stollenwerk TM, Beatka M, Hillard CJ. Meet your stress management professionals: the endocannabinoids. Trends Mol Med. 2020;26:953–68.

Article  PubMed  PubMed Central  Google Scholar 

Umathe SN, Manna SSS, Jain NS. Involvement of endocannabinoids in antidepressant and anti-compulsive effect of fluoxetine in mice. Behav Brain Res. 2011;223:125–34.

Article  CAS  PubMed  Google Scholar 

Hill MN, Carrier EJ, McLaughlin RJ, Morrish AC, Meier SE, Hillard CJ, et al. Regional alterations in the endocannabinoid system in an animal model of depression: effects of concurrent antidepressant treatment. J Neurochem. 2008;106:2322–36.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hillard CJ. Circulating endocannabinoids: from whence do they come and where are they going? Neuropsychopharmacology. 2018;43:155–72.

Article  CAS  PubMed  Google Scholar 

Gowatch LC, Evanski JM, Ely SL, Zundel CG, Bhogal A, Carpenter C, et al. Endocannabinoids and stress-related neurospsychiatric disorders: a systematic review and meta-analysis of basal concentrations and response to acute psychosocial stress. Cannabis Cannabinoid Res. (2024). https://doi.org/10.1089/can.2023.0246.

Pharmaceuticals J Jazz Pharmaceuticals Provides Update on Phase 2 Trial of Investigational JZP150 in Adult Patients with Post-Traumatic Stress Disorder\. (2023).

Mayo LM, Asratian A, Lindé J, Morena M, Haataja R, Hammar V, et al. Elevated anandamide, enhanced recall of fear extinction, and attenuated stress responses following inhibition of fatty acid amide hydrolase: a randomized, controlled experimental medicine trial. Biol Psychiatry. 2020. https://doi.org/10.1016/j.biopsych.2019.07.034.

Mayo LM, Asratian A, Lindé J, Holm L, Nätt D, Augier G, et al. Protective effects of elevated anandamide on stress and fear-related behaviors: translational evidence from humans and mice. Mol Psychiatry. 2020. https://doi.org/10.1038/s41380-018-0215-1.

Mayo LM, Rabinak CA, Hill MN, Heilig M. Targeting the endocannabinoid system in the treatment of posttraumatic stress disorder: a promising case of preclinical-clinical translation? Biol Psychiatry. 2022;91:262–72.

Sharafi A, Pakkhesal S, Fakhari A, Khajehnasiri N, Ahmadalipour A. Rapid treatments for depression: endocannabinoid system as a therapeutic target. Neurosci Biobehav Rev. 2022;137:104635.

Article  CAS  PubMed  Google Scholar 

Desai S, Borg B, Cuttler C, Crombie K, Rabinak C, Hill M, et al. A systematic review and meta-analysis on the effects of exercise on the endocannabinoid system. Cannabis Cannabinoid Res. 2021;7:388–408.

Marusak HA, Ely SL, Zundel CG, Gowatch LC, Shampine M, Carpenter C, et al. Endocannabinoid dysregulation and PTSD in urban adolescents: associations with anandamide concentrations and FAAH genotype. Psychopharmacology. 2024. https://doi.org/10.1007/s00213-024-06717-3.

Strawn JR, Lu L, Peris TS, Levine A, Walkup JT. Research review: pediatric anxiety disorders—What have we learnt in the last 10 years? J Child Psychol Psychiatry. 2021;62:114–39.

Article  PubMed  Google Scholar 

Ryan ND. Treatment of anxiety disorders in youths: filling the cup further. Am J Psychiatry. 2017;174:723–4.

Article  PubMed  Google Scholar 

Meyer HC, Lee FS, Gee DG. The role of the endocannabinoid system and genetic variation in adolescent brain development. Neuropsychopharmacology. 2018;43:21–33.

Article  PubMed  Google Scholar 

Marusak HA. The role of cannabinoids in shaping lifespan neurodevelopment. J Neurosci Res. 2022;100:709–12.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Strawn JR, Mills JA, Schroeder H, Mossman SA, Varney ST, Ramsey LB, et al. Escitalopram in adolescents with generalized anxiety disorder: a double-blind, randomized, placebo-controlled study. J Clin Psychiatry. 2020;81:20m13396.

Birmaher B, Brent DA, Chiappetta L, Bridge J, Monga S, Baugher M. Psychometric properties of the screen for child anxiety related emotional disorders (SCARED): a replication study. J Am Acad Child Adolesc Psychiatry. 1999. https://doi.org/10.1097/00004583-199910000-00011.

Albano AM, Silverman WK. Anxiety disorders interview schedule for DSM-IV: Clinician manual. (No Title). (1996). 1996.

The Pediatric Anxiety Rating Scale (PARS): development and psychometric properties. J Am Acad Child Adolesc Psychiatry. (2002);41:1061-9.

Guy W. ECDEU assessment manual for psychopharmacology. US Department of Health, Education, and Welfare, Public Health Service; (1976).

Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry. 2007;4:28–37.

PubMed  PubMed Central  Google Scholar 

Pastor A, Farré M, Fitó M, Fernandez-Aranda F, de la Torre R. Analysis of ECs and related compounds in plasma: artifactual isomerization and ex vivo enzymatic generation of 2-MGs[S]. J Lipid Res. 2014;55:966–77.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Qi M, Morena M, Vecchiarelli HA, Hill MN, Schriemer DC. A robust capillary liquid chromatography/tandem mass spectrometry method for quantitation of neuromodulatory endocannabinoids. Rapid Commun Mass Spectrom. 2015. https://doi.org/10.1002/rcm.7277.

Hill MN, Bierer LM, Makotkine I, Golier JA, Galea S, McEwen BS, et al. Reductions in circulating endocannabinoid levels in individuals with post-traumatic stress disorder following exposure to the world trade center attacks. Psychoneuroendocrinology. 2013;38:2952–61.

Article  CAS  PubMed  Google Scholar 

Hayes AF. Introduction to mediation, moderation, and conditional process analysis: a regression-based approach. Introd Mediat Moderat Cond Process Anal A Regres-Based Approach 2013;xvii:507.

Google Scholar 

Strawn JR, Geracioti L, Rajdev N, Clemenza K, Levine A. Pharmacotherapy for generalized anxiety disorder in adult and pediatric patients: an evidence-based treatment review. Expert Opin Pharmacother. 2018;19:1057–70.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Varigonda AL, Jakubovski E, Taylor MJ, Freemantle N, Coughlin C, Bloch MH. Systematic review and meta-analysis: early treatment responses of selective serotonin reuptake inhibitors in pediatric major depressive disorder. J Am Acad Child Adolesc Psychiatry. 2015;54:557–64.

Article  PubMed  Google Scholar 

Mayo LM, Rabinak CA, Hill MN, Heilig M. Targeting the endocannabinoid system in the treatment of PTSD: a promising case of preclinical-clinical translation? Biol Psychiatry. 2021. https://doi.org/10.1016/j.biopsych.2021.07.019.

Aguilera Vasquez N, Nielsen DE. The endocannabinoid system and eating behaviours: a review of the current state of the evidence. Curr Nutr Rep. 2022;11:665–74.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Amir Hamzah K, Toms LM, Kucharski N, Orr J, Turner NP, Hobson P, et al. Sex-dimorphism in human serum endocannabinoid and n-acyl ethanolamine concentrations across the lifespan. Sci Rep. 2023;13:1–11.

Article  Google Scholar 

Hanlon EC, Tasali E, Leproult R, Stuhr KL, Doncheck E, de Wit H, et al. Circadian rhythm of circulating levels of the endocannabinoid 2-arachidonoylglycerol. J Clin Endocrinol Metab. 2015;100:220–6.

Article  CAS  PubMed  Google Scholar 

Hill MN, Miller GE, Carrier EJ, Gorzalka BB, Hillard CJ. Circulating endocannabinoids and N-acyl ethanolamines are differentially regulated in major depression and following exposure to social stress. Psychoneuroendocrinology. 2009. https://doi.org/10.1016/j.psyneuen.2009.03.013.

Petrowski K, Kirschbaum C, Gao W, Hardt J, Conrad R. Blood endocannabinoid levels in patients with panic disorder. Psychoneuroendocrinology. 2020;122:104905.

Article  CAS  PubMed